anahataenergy.com

Saturday, October 4, 2008

The U.S. Senate passed a revised bailout bill designed to help the struggling U.S. financial economy, which has measures nearly identical to the bill rejected by the U.S. House of Representatives on Monday.

“Senate Democrats and Republicans believe it is essential that we work quickly on this important legislation to restore confidence to our financial system and strengthen the economy,” said Senate Majority Leader Harry Reid.

The new revisions include raising the FDIC insurance cap to $250,000, a move designed to please progressives. However, the $110 billion in tax breaks, earmarks and what has been called pork barrel spending is not offset by any increases in revenues and has added opposition to the bill from some Representatives in the House.

Earmarks added into the bailout bill included $192 million in tax rebates for the Virgin Islands rum industry, $148 million in tax cuts for the wool industry, $100 million tax cuts to the auto racing industry, and $48 million in Hollywood tax incentives.

Vice President of Taxpayers for Common Sense, Steve Ellis, offered his explanation for the pork and earmarks added in. “People who support some of these provisions will forget about the $700 billion and concerns they may have on that, and say, ‘If you give me a few million in tax breaks for my constituents, I’ll go along'”.

The tactic seems to have worked, however, managing to flip enough votes to pass the bill.

“The inclusion of parity, tax extenders and the FDIC increases has caused me to reconsider my position,” said Representative Jim Ramstad (R Minnesota), who voted against the previous bill on Monday. “All three additions have greatly improved the bill.”

But Representative Marcy Kaptur (D Ohio) was not changing her no vote. “I will not support this legislation because it’s the wrong medicine,” she said.

The Senate took H.R.1424, a bill originating in the House concerning “equity in the provision of mental health and substance-related disorder benefits under group health plans, to prohibit discrimination on the basis of genetic information with respect to health insurance and employment,” and extended it with the bailout provisions.

H.R.1424 was introduced on March 9, 2007, by Rep. Patrick Kennedy (RI-1) and had the support of First Lady Rosalind Carter. It is noted on the Congressional Website that “On 10/1/2008, the Senate passed H.R.1424 as the vehicle for the economic rescue legislation. In the EAS version of the bill (Engrossed Amendment as Agreed to by the Senate), Division A (pp.1-110) is referred to as the Emergency Economic Stabilization Act of 2008; Division B (pp. 110-255) is referred to as the Energy Improvement and Extension Act of 2008; and Division C (pp. 255-441) is referred to as the Tax Extenders and Alternative Minimum Tax Relief Act of 2008.” It was not treated as an appropriations bill in the House.

There were two votes in the Senate. The first was to amend H.R.1424, which required 3/5 to be accepted, which it was. The second was a vote on the bill. Passage of the Bill required only a 1/2 majority. It was passed with 74 yeas and 25 nays. Senator Kennedy did not vote.

Tuesday, November 18, 2008

Japan, which accounts for 7% of world output, has entered a recession after posting two consecutive quarters of negative growth. The Japanese economy contracted by 0.9% between April and June and a further 0.1% since September.

Kaoru Yosano, the Japanese minister of fiscal policy, said “The downtrend in the economy will continue for the time being as global growth slows down. We need to bear in mind that economic conditions could worsen further as the US and European financial crisis deepens, worries of economic downturn heighten and stock and foreign exchange markets make big swings.”

The Nikkei 225 stock index has fallen 40% since the beginning of the year, and has lost a quarter of its value during this month. After the news was announced the index dipped, then rose to close up 0.7%.

Japanese companies lose large sums whenever the yen’s value surges. With the yen viewed as relatively stable during financial turmoil, the value against the US dollar has risen greatly.

JPMorgan Chase economist Masamichi Adachi said, “It’s only going to get worse. Japan may be entering its deepest recession in a decade as the global financial crisis cools demand.” Japan has not been in recession since 2001.

Wednesday, December 7, 2016

Chemotherapy is usually associated with a collection of side effects ranging from digestive problems to hair loss, but a study published this week in Human Reproduction demonstrated that female cancer patients may find they have something in common with much younger women in one specific area — their ovaries.

Scientists from the University of Edinburgh examined donated ovarian tissue from fourteen female cancer patients, most of whom had Hodgkin lymphoma, and compared it to tissue from healthy women. They found the samples from women who had been treated with a specific chemotherapeutic regimen known as ABVD not only contained greater numbers of dormant ova — egg cells — than those from women treated with harsher regimens but also more than samples from healthy women. ABVD is named for combining several drugs known as adriamycin, bleomycin, vinblastine, and dacarbazine.

These reproductive cells were not merely more plentiful in ABVD patients. They also appeared immature, “new” in the words of lead researcher Evelyn Telfer. This challenges the conventional belief that girls are born with all the ova they will ever have and the numbers can only go down as the cells are either used up by the reproductive cycle or succumb to damage or natural aging. However, further research is needed to confirm this. The study covered relatively few patients by scientific standards, and David Albertini of the Center for Human Reproduction in New York has suggested the cells may not actually be freshly grown. Instead, they may have always been there and were merely rendered more detectable by ABVD treatment.

The ability to grow new egg cells may have significant implications for women in Western societies, many of whom postpone childbearing to establish careers, sometimes into their late thirties or forties. However, Telfer warns against making use of these findings too soon: “There’s so much we don’t know about the ovary. We have to be very cautious about jumping to clinical applications.”

The experiments had been discussed earlier this year at the annual conference of the European Society of Human Reproduction and Embryology.

Thursday, October 30, 2008

Actor David Tennant made an announcement Wednesday at the National Television Awards in the United Kingdom that he will end his time portraying the Tenth Doctor on the long-running BBC science fiction drama Doctor Who in 2009. The announcement came as part of Tennant’s speech accepting the outstanding drama performance award at the program.

Tennant, 37, is currently portraying the lead in a production of Hamlet with the Royal Shakespeare Company, and accepted the award by videolink. He was up against Doctor Who co-star Catherine Tate, who portrayed his companion Donna Noble. Doctor Who was recognized with the award for most popular drama program.

“I love this part, and I love this show so much that if I don’t take a deep breath and move on now I never will, and you’ll be wheeling me out of the Tardis in my bath chair,” said Tennant in his address to the audience in attendance at the Royal Albert Hall. “TARDIS” refers to the time machine and spacecraft operated by Tennant’s character known only as “the Doctor”, and stands for Time And Relative Dimension In Space.

Tennant will again inhabit the TARDIS as the Tenth Doctor for the upcoming Doctor Who Christmas special, “The Next Doctor“, and will portray the Doctor in four additional specials set to air in 2009. A new actor will play the Doctor for the program’s 2010 series.

Tennant had initially been interested in portraying the Doctor in the 2005 series, but that role went to Christopher Eccleston. The series had previously been dormant since 1996, with Paul McGann in the lead role. Tennant has said that it was his childhood dream to play the Doctor. This is not his first time being recognized at the National Television Awards for his role as the Doctor. In 2006 he received the award for most popular actor, and again in 2007. In 2006 Tennant beat out actor Tom Baker as the favorite doctor, in a survey of readers of Doctor Who Magazine.

The Doctor comes from a race of Timelords, and has the ability to “regenerate” and change appearance when his health is failing. Actors including Russell Tovey, James Nesbitt, Paterson Joseph, John Simm and David Morrissey have been mentioned in the media as possibilities to portray the 11th incarnation of the Doctor.

Russell T. Davies, the program’s current executive producer, commented to BBC News on the end of the Tenth Doctor and his work with Tennant: “I’ve been lucky and honoured to work with David over the past few years – and it’s not over yet, the Tenth Doctor still has five spectacular hours left! After which, I might drop an anvil on his head. Or maybe a piano. A radioactive piano. But we’re planning the most enormous and spectacular ending, so keep watching.” Steven Moffat will replace Davies as executive director of Doctor Who in 2010.

Tennant began his work as an actor with roles in theatre, and progressed to starring roles on television programs including Blackpool and Casanova. He has recently returned to theatre roles with the Royal Shakespeare Company, and has received praise for his work in Hamlet and Love’s Labour’s Lost.

Thursday, December 18, 2008

A team of eight transplant surgeons in Cleveland Clinic in Ohio, USA, led by reconstructive surgeon Dr. Maria Siemionow, age 58, have successfully performed the first almost total face transplant in the US, and the fourth globally, on a woman so horribly disfigured due to trauma, that cost her an eye. Two weeks ago Dr. Siemionow, in a 23-hour marathon surgery, replaced 80 percent of her face, by transplanting or grafting bone, nerve, blood vessels, muscles and skin harvested from a female donor’s cadaver.

The Clinic surgeons, in Wednesday’s news conference, described the details of the transplant but upon request, the team did not publish her name, age and cause of injury nor the donor’s identity. The patient’s family desired the reason for her transplant to remain confidential. The Los Angeles Times reported that the patient “had no upper jaw, nose, cheeks or lower eyelids and was unable to eat, talk, smile, smell or breathe on her own.” The clinic’s dermatology and plastic surgery chair, Francis Papay, described the nine hours phase of the procedure: “We transferred the skin, all the facial muscles in the upper face and mid-face, the upper lip, all of the nose, most of the sinuses around the nose, the upper jaw including the teeth, the facial nerve.” Thereafter, another team spent three hours sewing the woman’s blood vessels to that of the donor’s face to restore blood circulation, making the graft a success.

The New York Times reported that “three partial face transplants have been performed since 2005, two in France and one in China, all using facial tissue from a dead donor with permission from their families.” “Only the forehead, upper eyelids, lower lip, lower teeth and jaw are hers, the rest of her face comes from a cadaver; she could not eat on her own or breathe without a hole in her windpipe. About 77 square inches of tissue were transplanted from the donor,” it further described the details of the medical marvel. The patient, however, must take lifetime immunosuppressive drugs, also called antirejection drugs, which do not guarantee success. The transplant team said that in case of failure, it would replace the part with a skin graft taken from her own body.

Dr. Bohdan Pomahac, a Brigham and Women’s Hospital surgeon praised the recent medical development. “There are patients who can benefit tremendously from this. It’s great that it happened,” he said.

Leading bioethicist Arthur Caplan of the University of Pennsylvania withheld judgment on the Cleveland transplant amid grave concerns on the post-operation results. “The biggest ethical problem is dealing with failure — if your face rejects. It would be a living hell. If your face is falling off and you can’t eat and you can’t breathe and you’re suffering in a terrible manner that can’t be reversed, you need to put on the table assistance in dying. There are patients who can benefit tremendously from this. It’s great that it happened,” he said.

Dr Alex Clarke, of the Royal Free Hospital had praised the Clinic for its contribution to medicine. “It is a real step forward for people who have severe disfigurement and this operation has been done by a team who have really prepared and worked towards this for a number of years. These transplants have proven that the technical difficulties can be overcome and psychologically the patients are doing well. They have all have reacted positively and have begun to do things they were not able to before. All the things people thought were barriers to this kind of operations have been overcome,” she said.

The first partial face transplant surgery on a living human was performed on Isabelle Dinoire on November 27 2005, when she was 38, by Professor Bernard Devauchelle, assisted by Professor Jean-Michel Dubernard in Amiens, France. Her Labrador dog mauled her in May 2005. A triangle of face tissue including the nose and mouth was taken from a brain-dead female donor and grafted onto the patient. Scientists elsewhere have performed scalp and ear transplants. However, the claim is the first for a mouth and nose transplant. Experts say the mouth and nose are the most difficult parts of the face to transplant.

In 2004, the same Cleveland Clinic, became the first institution to approve this surgery and test it on cadavers. In October 2006, surgeon Peter Butler at London‘s Royal Free Hospital in the UK was given permission by the NHS ethics board to carry out a full face transplant. His team will select four adult patients (children cannot be selected due to concerns over consent), with operations being carried out at six month intervals. In March 2008, the treatment of 30-year-old neurofibromatosis victim Pascal Coler of France ended after having received what his doctors call the worlds first successful full face transplant.

Ethical concerns, psychological impact, problems relating to immunosuppression and consequences of technical failure have prevented teams from performing face transplant operations in the past, even though it has been technically possible to carry out such procedures for years.

Mr Iain Hutchison, of Barts and the London Hospital, warned of several problems with face transplants, such as blood vessels in the donated tissue clotting and immunosuppressants failing or increasing the patient’s risk of cancer. He also pointed out ethical issues with the fact that the procedure requires a “beating heart donor”. The transplant is carried out while the donor is brain dead, but still alive by use of a ventilator.

According to Stephen Wigmore, chair of British Transplantation Society’s ethics committee, it is unknown to what extent facial expressions will function in the long term. He said that it is not certain whether a patient could be left worse off in the case of a face transplant failing.

Mr Michael Earley, a member of the Royal College of Surgeon‘s facial transplantation working party, commented that if successful, the transplant would be “a major breakthrough in facial reconstruction” and “a major step forward for the facially disfigured.”

In Wednesday’s conference, Siemionow said “we know that there are so many patients there in their homes where they are hiding from society because they are afraid to walk to the grocery stores, they are afraid to go the the street.” “Our patient was called names and was humiliated. We very much hope that for this very special group of patients there is a hope that someday they will be able to go comfortably from their houses and enjoy the things we take for granted,” she added.

In response to the medical breakthrough, a British medical group led by Royal Free Hospital’s lead surgeon Dr Peter Butler, said they will finish the world’s first full face transplant within a year. “We hope to make an announcement about a full-face operation in the next 12 months. This latest operation shows how facial transplantation can help a particular group of the most severely facially injured people. These are people who would otherwise live a terrible twilight life, shut away from public gaze,” he said.

Wednesday, August 11, 2021

On July 22, Wikinews interviewed Professor Gigi Foster of School of Economics at the University of New South Wales, Sydney, Australia about measures that the government took to stop the spread of COVID-19, a virus that caused what the World Health Organization declared a pandemic last year.

Professor Foster is on faculty with the School of Economics at the University of New South Wales. She wrote an Op-Ed in the Sydney Morning Herald, arguing for a case against the so-called “lockdowns” – measures which the state governments in Australia were implementing to stop the spread of COVID-19. These measures included things like limiting the size of gatherings, directing certain business types such as gyms to close or operate at reduced capacity, limiting where people may travel and restricting residents to only leaving their home if they have a reasonable excuse to do so.

In New South Wales, these restrictions were implemented as Public Health Orders, signed by Brad Hazzard, the Minister for Health and Medical Research. Mr Brad Hazzard has authority make these Orders under the Public Health Act 2010, section 7.

Wikinews reached out to Professor Gigi Foster, asking for comment.

The interview was conducted amid an outbreak of COVID-19 in New South Wales, that has resulted in an increase of restrictions from June 26. At the day of interview, residents were legally allowed to go outdoors only for essential shopping, medical care, and exercise, in groups of no more than two people unless of a common household. On July 28, authorities extended these restrictions until the end of August.

The current outbreak of the COVID-19 Delta strain started from ‘patient zero’, reportedly a driver, which includes transporting international flight crew, as NSW Health wrote on June 16. A week later, on June 24, the driver commented that he thought that he caught the virus from a local cafe, where another patron was visibly unwell.

New South Wales Premier Gladys Berejiklian has said that “our mission is to allow our citizens to live as safely and freely as possible”, having announced that only authorized workers — people whose occupation is essential — could leave home in selected higher risk regions in south-west of Sydney until July 30.

Work of the construction industry has been stopped for several days, and resumed this week with requirement that the construction workers get tested for COVID-19 regularly.

Thursday, November 12, 2009

Researchers have found a crucial genetic difference between humans and chimps that could help explain our language and speech abilities. The difference lies in a gene called FOXP2 which encodes for a protein of the same name. This acts as a transcription factor, controlling the activity of other genes.

The human and chimp versions of the protein differ in only two of their 740 amino acid components, but when researchers at the University of California, Los Angeles, replaced the human gene with the chimp version in neurons grown in the laboratory, they found it affected the expression of at least 116 other genes.

The results are detailed in a paper published on Thursday in the scientific journal Nature.

Author of the study Dr. Daniel Geschwind, of the David Geffen School of Medicine at UCLA, said the gene had a “major role” in differences between chimps and humans. “We showed that the human and chimp versions of FOXP2 not only look different but function differently too.”

Some of the affected genes control the formation of connections in the brain, whilst others relate to facial movements. Several have already been found to be involved in language disorders. Mutations in FOXP2 itself were also known to affect speech and language; the gene was first identified in members of a family suffering from language problems who were found to share a genetic mutation.

Frances Vargha-Khadem at University College London has studied patients with FOXP2 mutations, and agrees with the new research. As well as language problems, some of her subjects have changes in the shape of their jaws, mouths and tongues. She thinks that chimps may also have these differences.

“We believe FOXP2 is not only important for the higher order cognitive aspect of language but also for the motor aspect of speech and language,” said Genevieve Konopka, one of the authors of the paper at UCLA.

Previous research indicates that the changes in FOXP2 occurred around 200,000 years ago with the rise of modern humans. Geschwind also suggests that several of the related genes may have evolved together. Preliminary studies have shown signs that they too emerged relatively recently.

Scientists are now keen to further study FOXP2 and the genes that it affects. Geschwind believes this could eventually lead to breakthroughs in treatment for disorders such as autism and schizophrenia, which affect language skills.

The study was funded by the National Institute of Mental Health, the A.P. Giannini Foundation and the National Alliance for Research on Schizophrenia and Depression.